STEVENSON, Md., March 28, 2016 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf of purchasers of LPL Financial Holdings Inc. (Nasdaq:LPLA) (“LPL” or the “Company”) common stock during the period between December 8, 2015 and February 11, 2016, inclusive (the “Class Period”). Investors with losses in excess of $100,000 who wish to become proactively involved in the litigation have until May 23, 2016 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the Company’s common stock during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that LPL’s earnings and revenue were substantially declining, that LPL’s client assets were deteriorating substantially, and that LPL’s gross profits were experiencing a substantial decline.
According to the complaint, following the Company’s February 11, 2016 announcement that its full year 2015 financial results were substantially below expectations primarily as a result of lower commission revenues and lower revenues from alternative investments as well as higher-than-expected expenses, the value of LPL shares declined significantly.
If you have suffered a loss from investment in LPL common stock purchased on or after December 8, 2015 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 [email protected]


Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Samsung Electronics Shares Jump on HBM4 Mass Production Report
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Anta Sports Expands Global Footprint With Strategic Puma Stake
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Washington Post Publisher Will Lewis Steps Down After Layoffs
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 



